Promoted Content
Promoted Content

Find Oncology Drugs in Phase II Clinical Development in JAPAN

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 29, 2021

            Details:

            First patient was dosed in DESTINYLung02, a global phase 2 trial evaluating the safety and efficacy of ENHERTU in patients with HER2 mutated metastatic NSCLC with disease recurrence, progression during or after at least one prior platinum-containing treatment regimen.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Trastuzumab Deruxtecan

            Therapeutic Area: Oncology Product Name: Enhertu

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2021

            Details:

            Interim DESTINY-Lung01 research data from the HER2 overexpressing metastatic non-small cell lung cancer (NSCLC) cohort of ENHERTU® will be featured as late-breaker presentation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Lenvatinib,Pembrolizumab

            Therapeutic Area: Oncology Product Name: Lenvima

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 11, 2021

            Details:

            Data on the lenvatinib, pembrolizumab combination that will be presented includes results from the Phase 2 LEAP-005 trial of multiple cohorts of patients with previously treated solid tumors, including: gastric cancer, biliary tract cancers and colorectal cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Datopotamab Deruxtecan

            Therapeutic Area: Oncology Product Name: DS-1062a

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            The phase 1 trial of datopotamab deruxtecan will evaluate whether targeting TROP2 with DXd ADC technology could be a new treatment strategy for patients with previously treated metastatic non-small cell lung cancer with actionable genomic alterations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Naxitamab

            Therapeutic Area: Oncology Product Name: Danyelza

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Y-mAbs Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement December 04, 2020

            Details:

            Under the terms of the agreement, Takeda will employ its proven platform of sales, access, marketing and regulatory expertise to distribute DANYELZA and omburtamab, if approved, in the territory.